文献速递血脂与心血管预防冠心病

ANGPTL3基因抑制、血脂与心血管代谢风险

Genetic inhibition of angiopoietin-like protein-3, lipids, and cardiometabolic risk.
PubMed 文献 · Eur Heart J · 2024-01-01

本研究利用孟德尔随机化分析影响ANGPTL3肝脏表达或血浆蛋白水平的遗传变异,并评估UK Biobank中ANGPTL3蛋白截短变异携带者的血脂与冠心病风险,发现这些变异显著降低甘油三酯、较弱降低apoB,但对冠心病及其他心血管代谢疾病无影响。

要点

  • 影响ANGPTL3表达或蛋白的遗传变异显著降低甘油三酯,但对冠心病无影响。
  • 对于apoB显著升高的患者,可能需要近乎完全抑制ANGPTL3功能才能降低ASCVD风险。

核心结论

  • 影响ANGPTL3蛋白结构或表达水平的遗传变异强烈降低血浆甘油三酯,但对apoB影响较弱,且对ASCVD无影响。

研究设计与样本

  • 采用两样本孟德尔随机化,利用影响ANGPTL3肝脏表达或血浆蛋白水平的SNP作为工具变量。
  • 对246份离体肝样本进行RNA测序和全基因组基因分型以识别与ANGPTL3肝脏表达相关的SNP。
  • 在UK Biobank中识别出647名携带与较低甘油三酯相关的ANGPTL3蛋白截短变异的携带者。

主要发现

  • 两样本MR显示,影响ANGPTL3肝脏或血液表达的常见遗传变异对血浆甘油三酯有非常强效应,对LDL-C效应较温和,对apoB效应更弱,对CAD或其他心血管代谢疾病无效应。

临床怎么用

  • 遗传学证据提示单纯抑制ANGPTL3降低甘油三酯可能不足以降低ASCVD风险,尤其当apoB未显著降低时。
  • 对于apoB水平非常高的患者,可能需要近乎完全抑制ANGPTL3功能才能降低ASCVD风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: RNA-based, antibody-based, and genome editing-based therapies are currently under investigation to determine if the inhibition of angiopoietin-like protein-3 (ANGPTL3) could reduce lipoprotein-lipid levels and atherosclerotic cardiovascular disease (ASCVD) risk. Mendelian randomisation (MR) was used to determine whether genetic variations influencing ANGPTL3 liver gene expression, blood levels, and protein structure could causally influence triglyceride and apolipoprotein B (apoB) levels as well as coronary artery disease (CAD), ischaemic stroke (IS), and other cardiometabolic diseases. METHODS: RNA sequencing of 246 explanted liver samples and genome-wide genotyping was performed to identify single-nucleotide polymorphisms (SNPs) associated with liver expression of ANGPTL3. Genome-wide summary statistics of plasma protein levels of ANGPTL3 from the deCODE study (n = 35 359) were used. A total of 647 carriers of ANGPTL3 protein-truncating variants (PTVs) associated with lower plasma triglyceride levels were identified in the UK Biobank. Two-sample MR using SNPs that influence ANGPTL3 liver expression or ANGPTL3 plasma protein levels as exposure and cardiometabolic diseases as outcomes was performed (CAD, IS, heart failure, non-alcoholic fatty liver disease, acute pancreatitis, and type 2 diabetes). The impact of rare PTVs influencing plasma triglyceride levels on apoB levels and CAD was also investigated in the UK Biobank. RESULTS: In two-sample MR studies, common genetic variants influencing ANGPTL3 hepatic or blood expression levels of ANGPTL3 had a very strong effect on plasma triglyceride levels, a more modest effect on low-density lipoprotein cholesterol, a weaker effect on apoB levels, and no effect on CAD or other cardiometabolic diseases. In the UK Biobank, the carriers of rare ANGPTL3 PTVs providing lifelong reductions in median plasma triglyceride levels [-0.37 (interquartile range 0.41) mmol/L] had slightly lower apoB levels (-0.06 ± 0.32 g/L) and similar CAD event rates compared with non-carriers (10.2% vs. 10.9% in carriers vs. non-carriers, P = .60). CONCLUSIONS: PTVs influencing ANGPTL3 protein structure as well as common genetic variants influencing ANGPTL3 hepatic expression and/or blood protein levels exhibit a strong effect on circulating plasma triglyceride levels, a weak effect on circulating apoB levels, and no effect on ASCVD. Near-complete inhibition of ANGPTL3 function in patients with very elevated apoB levels may be required to reduce ASCVD risk.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Gobeil É, Bourgault J, Mitchell PL, et al. Genetic inhibition of angiopoietin-like protein-3, lipids, and cardiometabolic risk. Eur Heart J. 2024. PMID: 38243829. doi:10.1093/eurheartj/ehad845

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。